Published in Health and Medicine Week, April 19th, 2004
The study, a cost-effectiveness model developed by the Harvard University Center for Risk Analysis and School of Public Health, the Dana-Farber Cancer Institute, and Beth Israel Deaconess Medical Center, compared the use of FISH testing alone with its use in confirming the results of immunohistochemistry (IHC) testing to identify candidates for Herceptin (trastuzumab) therapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.